207 related articles for article (PubMed ID: 31639760)
1. Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay.
Thoren KL; Pianko MJ; Maakaroun Y; Landgren CO; Ramanathan LV
J Appl Lab Med; 2019 Mar; 3(5):857-863. PubMed ID: 31639760
[TBL] [Abstract][Full Text] [Related]
2. [Application of Hydrashift 2/4 daratumumab assay in eliminating interference of daratumumab on serum immunofixation electrophoresis].
Xu S; Liu Y; Wen L; Zhao L; Deng X; Rong R; Lu J
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):840-845. PubMed ID: 34788924
[No Abstract] [Full Text] [Related]
3. Mitigating the interference of Daratumumab with immunofixation electrophoresis. A single-center experience using Hydrashift 2/4 kit.
Duek A; Lellouche E; Ben Baruch S; Mashiach R; Segman Y; Bryk G; Leiba M
Isr Med Assoc J; 2022 Oct; 24(10):629-633. PubMed ID: 36309856
[TBL] [Abstract][Full Text] [Related]
4. Isatuximab-Specific Immunofixation Electrophoresis Assay to Remove Interference in Serum M-Protein Measurement in Patients with Multiple Myeloma.
Thoren K; Menad S; Nouadje G; Macé S
J Appl Lab Med; 2024 Apr; ():. PubMed ID: 38573925
[TBL] [Abstract][Full Text] [Related]
5. Use of a Daratumumab-Specific Immunofixation Assay to Assess Possible Immunotherapy Interference at a Major Cancer Center: Our Experience and Recommendations.
Kirchhoff DC; Murata K; Thoren KL
J Appl Lab Med; 2021 Nov; 6(6):1476-1483. PubMed ID: 34293131
[TBL] [Abstract][Full Text] [Related]
6. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
McCudden C; Axel AE; Slaets D; Dejoie T; Clemens PL; Frans S; Bald J; Plesner T; Jacobs JF; van de Donk NW; Moreau P; Schecter JM; Ahmadi T; Sasser AK
Clin Chem Lab Med; 2016 Jun; 54(6):1095-104. PubMed ID: 27028734
[TBL] [Abstract][Full Text] [Related]
7. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).
van de Donk NW; Otten HG; El Haddad O; Axel A; Sasser AK; Croockewit S; Jacobs JF
Clin Chem Lab Med; 2016 Jun; 54(6):1105-9. PubMed ID: 26812873
[TBL] [Abstract][Full Text] [Related]
8. Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference.
Noori S; Verkleij CPM; Zajec M; Langerhorst P; Bosman PWC; de Rijke YB; Zweegman S; VanDuijn M; Luider T; van de Donk NWCJ; Jacobs JFM
Clin Chem Lab Med; 2021 Nov; 59(12):1963-1971. PubMed ID: 34392637
[TBL] [Abstract][Full Text] [Related]
9. MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins.
Moore LM; Cho S; Thoren KL
Clin Chim Acta; 2019 May; 492():91-94. PubMed ID: 30790545
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of isatuximab-derived interference in serum protein electrophoresis and immunofixation, and an absence of sustained in vivo interference due to belantamab mafodotin and denosumab.
Jimenez A; Scholl AR; Wang B; Schilke M; Carlsen ED
Clin Biochem; 2024 May; 127-128():110761. PubMed ID: 38565341
[TBL] [Abstract][Full Text] [Related]
11. Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood.
Murata K; McCash SI; Carroll B; Lesokhin AM; Hassoun H; Lendvai N; Korde NS; Mailankody S; Landau HJ; Koehne G; Chung DJ; Giralt SA; Ramanathan LV; Landgren O
Clin Biochem; 2018 Jan; 51():66-71. PubMed ID: 27664535
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the HYDRASHIFT 2/4 Daratumumab assay: a powerful approach to assess treatment response in multiple myeloma.
Lee HW; Kim SM; Park HD
Clin Chem Lab Med; 2024 Apr; ():. PubMed ID: 38630027
[TBL] [Abstract][Full Text] [Related]
13. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
[TBL] [Abstract][Full Text] [Related]
14. Interference of Therapeutic Monoclonal Antibodies With Routine Serum Protein Electrophoresis and Immunofixation in Patients With Myeloma: Frequency and Duration of Detection of Daratumumab and Elotuzumab.
Tang F; Malek E; Math S; Schmotzer CL; Beck RC
Am J Clin Pathol; 2018 Jul; 150(2):121-129. PubMed ID: 29901687
[TBL] [Abstract][Full Text] [Related]
15. MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins.
Fatica EM; Martinez M; Ladwig PM; Murray JD; Kohlhagen MC; Kyle RA; Kourelis T; Lust JA; Snyder MR; Dispenzieri A; Murray DL; Willrich MAV
Clin Biochem; 2021 Nov; 97():67-73. PubMed ID: 34384797
[TBL] [Abstract][Full Text] [Related]
16. Electrophoretic patterns post daratumumab.
Sheldon J; Wheeler RD; Powles R
Ann Clin Biochem; 2018 Mar; 55(2):299-301. PubMed ID: 28490184
[TBL] [Abstract][Full Text] [Related]
17. False positive results: a challenge for laboratory physicians and hematologists in treating multiple myeloma with daratumumab.
Liang S; Feng W; Ma H; Zhang L; Jia C
Hematology; 2022 Dec; 27(1):332-336. PubMed ID: 35255237
[TBL] [Abstract][Full Text] [Related]
18. Identifying therapeutic monoclonal antibodies using target protein collision electrophoresis reflex assay to separate the wheat from the chaff.
Teuwen JTJ; Ritzen LFL; Knapen-Portz YM; Ludwiczek PK; Damoiseaux JGMC; van Beers JJBC; de Boer D
J Immunol Methods; 2023 Nov; 522():113552. PubMed ID: 37652294
[TBL] [Abstract][Full Text] [Related]
19. Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma.
Rabut É; Castro-Fernandez A; Le Gall V; Meknache N
Ann Biol Clin (Paris); 2017 Jun; 75(3):351-355. PubMed ID: 28540859
[TBL] [Abstract][Full Text] [Related]
20. Incidence and Management of Therapeutic Monoclonal Antibody Interference in Monoclonal Gammopathy Monitoring.
Liu L; Wertz WJ; Kondisko A; Shurin MR; Wheeler SE
J Appl Lab Med; 2020 Jan; 5(1):29-40. PubMed ID: 32445341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
